Skip to main content
Top

Cancer Chemotherapy and Pharmacology

Issue 4/2007

Content (16 Articles)

Original Article

Phase I and pharmacologic study of irinotecan and amrubicin in advanced non-small cell lung cancer

Tomoko Yanaihara, Masanori Yokoba, Sayaka Onoda, Michiko Yamamoto, Shinichiro Ryuge, Shintaro Hagiri, Masato Katagiri, Mayuko Wada, Hisashi Mitsufuji, Masaru Kubota, Susumu Arai, Hirosuke Kobayashi, Nobuo Yanase, Tadashi Abe, Noriyuki Masuda

Original Article

Androgen and c-Kit receptors in desmoplastic small round cell tumors resistant to chemotherapy: novel targets for therapy

Robert L. Fine, Samir S. Shah, Thomas A. Moulton, Ing-Ru Yu, David R. Fogelman, Michael Richardson, Howard A. Burris, Brian L. Samuels, Chatchawin Assanasen, Prakash Gorroochurn, Hanina Hibshoosh, Manuela Orjuela, James Garvin, Frederick D. Goldman, Daniel Dubovsky, David Walterhouse, Gregory Halligan

Original Article

A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer

Hideki Ueno, Takuji Okusaka, Akihiro Funakoshi, Hiroshi Ishii, Kenji Yamao, Osamu Ishikawa, Shinichi Ohkawa, Soh Saitoh

Original Article

Effects of mycophenolate mofetil on cisplatin-induced renal dysfunction in rats

Sherif Y. Saad, Maha M. Arafah, Tawfeeg A. Najjar

Original Article

Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates

Stacie L. Stapleton, Joel M. Reid, Patrick A. Thompson, Matthew M. Ames, Renee M. McGovern, Leticia McGuffey, Jed Nuchtern, Robert Dauser, Susan M. Blaney

Original Article

A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors

Matthew G. Fury, David B. Solit, Yungpo Bernard Su, Neal Rosen, F. M. Sirotnak, Robert P. Smith, Christopher G. Azzoli, Jorge E. Gomez, Vincent A. Miller, Mark G. Kris, Barbara A. Pizzo, Roxanne Henry, David G. Pfister, Naiyer A. Rizvi

Original Article

Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide

Shinya Fujisawa, Ryuzo Ohno, Kazuyuki Shigeno, Naohi Sahara, Satoki Nakamura, Kensuke Naito, Miki Kobayashi, Kaori Shinjo, Akihiro Takeshita, Yoshinari Suzuki, Hisakuni Hashimoto, Kenji Kinoshita, Masahito Shimoya, Toshikazu Kaise, Kazunori Ohnishi

Original Article

Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia

Xianhua Cao, Lanyan Fang, Seth Gibbs, Ying Huang, Zunyan Dai, Ping Wen, Xincheng Zheng, Wolfgang Sadee, Duxin Sun

Original Article

Clinical evaluation of chemosensitivity testing for patients with unresectable non-small cell lung cancer (NSCLC) using collagen gel droplet embedded culture drug sensitivity test (CD-DST)

Masafumi Kawamura, Masatoshi Gika, Tomohiro Abiko, Yoshimasa Inoue, Takahiko Oyama, Yotaro Izumi, Hisayuki Kobayashi, Koichi Kobayashi

Original Article

Additive antitumor effect of concurrent treatment of 4-hydroxy tamoxifen with 5-fluorouracil but not with doxorubicin in estrogen receptor-positive breast cancer cells

Junichi Kurebayashi, Mamoru Nukatsuka, Hideki Nagase, Tsunehisa Nomura, Mai Hirono, Yutaka Yamamoto, Yoshikazu Sugimoto, Toshinori Oka, Hiroshi Sonoo

Original Article

Adaphostin cytoxicity in glioblastoma cells is ROS-dependent and is accompanied by upregulation of heme oxygenase-1

Jason Long, Tejas Manchandia, Kechen Ban, Shan Gao, Claudia Miller, Joya Chandra

Original Article

In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases

Scott A. Shaffer, Cassie Baker-Lee, Jacob Kennedy, Man Shun Lai, Peter de Vries, Kent Buhler, Jack W. Singer

Original Article

A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression

Stephen Shibata, Warren Chow, Paul Frankel, Agnes Juhasz, Lucille Leong, Dean Lim, Kim Margolin, Robert Morgan, Edward Newman, George Somlo, Yun Yen, Timothy Synold, David Gandara, Heinz-Josef Lenz, James Doroshow

Erratum

Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies

Sarah A. Holstein, Howard R. Knapp, Gerald H. Clamon, Daryl J. Murry, Raymond J. Hohl

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine